Goodnough LT, Brecher ME, Kanter MH. Transfusion Medicine: first of two parts - blood transfusion. N Engl J Med. 1999;340:438-447.

Goodnough LT, Brecher ME, Kanter MH. Transfusion Medicine: second of two parts - blood conservation. N Engl J Med. 1999;340:525-533.

Schreiber GB, Busch MP, Korelitz JT. The risk of transfusion transmitted viral infections. N Engl J Med. 1996;334:1685-1690.

Klein HG. Immunomodulatory aspects of transfusion. Anesthesiol. 1999;91:861-865.

Innerhofer P, Walleczek C, Luz G. Transfusion of buffy coat-depleted blood component and risk of postoperative infection in orthopedic patients. Transfusion. 1999;39:625-632.

Houbiers JG, van de Velde CJ, Hermans J. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: A prospective study. Transfusion. 1997;37:126-134.

Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum. 1998;41:570-585.

Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled trials. Transfusion. 1996;36:175-186.

Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion. 1994;34:464-470.

Vuylsteke A. Artificial blood substitutes - benefits and risks. :144-147.

Remy B, Deby-Dupont G, Lamy ML. Red blood cell substitutes: fluorocarbon emulsions and hemoglobin solutions. Br Med Bull. 1999;55:277-298.

Lamy ML, Daily EK, Larbuisson RP. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. Anesthesiol. 2000;92:646-656.

Mazer CD, Cheng DCH, Belo SE. Oxygen supply and demand in patients undergoing CBAG surgery using intraoperative autologous donation with Hemolink® and Pentaspan. Anesthesiol. 2000;93:A195.

Levy JR, Goodnough LT, Greilich P. A room-temperature stable hemoglobin (HBOC-201) eliminates allogenic red blood cell transfusion in post-operative cardiac surgery patients. Circulation. 1998;98:I-132.

Vlahakes GJ. Haemoglobin solutions in surgery. Br J Surg. 2001;88:1553-1555.

Goodnough LT, Scott MG, Monk TG. Oxygen carriers as blood substitutes - past, present and future. Clin Orth Rel Research. 1998;398:89-100.

Chang TMS. Why do We Need Blood Substitutes?. Blood Substitutes: Principles, Methods, Products and Clinical Trials. 1997;1:3-8.

Shoemaker SA, Gerber MJ, Evans GL. Initial clinical experience with a rationale designed genetically engineered recombinant human Hb. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:457-465.

Chang TMS. What are Modified Hemoglobin Blood Substitutes?. Blood Substitutes, Principles, Methods, Products and Clinical Trials. 1997;1:9-31.

Savitsky JP, Doozi J, Black J. A clinical safety trial of strome free hemoglobin. Clin Pharm Ther. 1978;23:73.

Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions?. Anesth Analg. 1996;82:390-405.

Chapman KW, Snell SM, Jesse RG. Pilot scale production of pyrogen-free human hemoglobin for research. Biomater Artif Cells Immobil Biotechnol. 1992;20:415-421.

Lamy ML, Daily EK, Brichant JF. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb cardiac surgery trial collaborative. Anesthesiol. 2000;92:646-656.

Sloan EP, Koenigsberg M, Gens D. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. JAMA. 1999;282:1857-1864.

Dietz NM, Martin CM, Joyner MJ. The effects of cross-linked hemoglobin on regional vascular conductance in dogs. Anesth Analg. 1997;85:265-273.

Figueiredo LFP, Mathru M, Solanki D et al. Pulmonary hypertension and systemic vasoconstriction may offset the benefits of a cellular hemoglobin substitutes. J Trauma. 1997;42:847-853.

DeAngeles DA, Scott AM, McGrath AM. Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, blood, or hetastarch. J Trauma. 1997;42:406-414.

Lewis RJ, Berry DA, Fost N. Monitoring a clinical trial conducted under Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. Ann Emerg Med. 2001;38:397-404.

Serna DL, Powell LL, Kahwaji C. Cardiac function after eight hour storage by using polyethylene glycol hemoglobin versus crystalloid perfusion. ASAIO J. 2000;34:547-552.

Glasgow SC, Shah AS, Noone RB. Comparison of various hemoglobin polyoxyethylene conjugate solutions as resuscitative fluids after hemorrhagic shock. J Trauma. 2000;48:884-893.

Noone RB, Mythen MG, Vaslef SN. Effect of alpha-alpha cross-linked hemoglobin and pyridoxalated hemoglobinpoly-oxyethylene conjugate solutions on gastrointestinal regional perfusion in hemorrhagic shock. J Trauma. 1998;45:457-469.

Conover CD, Lejeune L, Shum K. Physiological effect of polyethylene glycol conjugation on stroma-free bovine hemoglobin in the conscious dog after partial exchange transfusion. Artif Organs. 1997;21:369-378.

Yang T, Olsen KW. Thermal stability of Hb cross-linked in the T state by bis (3,5 dibromosalicyl) fumarate. Biochem Biophys Res Comm. 1991;174:518-523.

Benesch R, Benesch RE, Yung S. Hemoglobin covalgatly bridged across the polyphosphate binding site. Biochem Biophys Res Comm. 1975;63:1123.

Johnson JL, Moore EE, Offner PJ. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg. 1998;176:612-617.

Gould SA, Moore EE, Hoyt DB. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998;187:113-120.

Moore FA, Moore EE, Sauaia A. Blood transfusion: an independent risk factor for postinjury multiple organ failure. Arch Surg. 1996;132:620-625.

Johnson JL, Moore EE, Offner P. Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function. J Trauma. 2001;50:449-456.

Hughes GS, Antal EJ, Locker P. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med. 1996;24:756-764.

Cohn SM. Is blood obsolete?. J Trauma. 1997;42:730-732.

LaMuraglia GM, O´Hara PJ, Baker WH. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg. 2000;31:299-308.

Manning JE, Katz LM, Pearce B. Selective aortic arch perfusion with hemoglobin-based oxygen carrier for resuscitation from exsanguinating cardiac arrest in swine. Crit Care Med. 2001;29:2067-2074.

Cheung ATW, Jahr JS, Driessen B. The effects of hemoglobin glutamer-200 (bovine) on the microcirculation in a canine hypovolemia model: a noninvasive computer-assisted intravital microscopy study. Anesth Analg. 2001;93:832-838.

McNeil JD, Smith DL, Jenkins DH. Hypotensive resuscitation using a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC 201) leads to reversal of anaerobic metabolism. J Trauma. 2001;50:1063-1075.

Sprung J, Kindscher J, Wahr JA. The use of bovine hemoglobin glutamer-250 (Hemopure®) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg. 2002;94:799-808.

Jahr JS, Dulchavsky SA, Garino JP. Hemodynamic effects of hemoglobin glutamer-250 (Hemopure®, HBOC-201) compared to red blood cells in pivotal safety and efficacy study in orthopedic surgery patients. Anesth Analg. 2002;94:S-330.

Cheng DCH, Mazer RE, Carmichael FJL. The hemodynamic effects of the red cell substitute Hemolink® (o-raffinose cross-linked human hemoglobin) on vital signs in patients undergoing CABG surgery. Anesthesiol. 2000;93:A180.

Carmichael FJL, Biro GP, Agensky L. Use of the blood substitute Hemolink® in CABG surgery. Anesth Analg. 2000;90:SCA11.

Cheng DCH. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink®) in cardiac surgery. Can J Anaesth. 2001;48:S41-S48.

Ketcham EM, Cairns CB. Hemoglobin-based oxygen carriers: development and clinical potentials. Ann Emerg Med. 1999;33:327-337.

Loscalzo J. Nitric oxide binding and the adverse effects of cell-free hemoglobin’s: what make us different from earthworms. J Lab Clin Med. 1997;129:580-583.

Stampler JS, Jia L, Eu JP. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034-2037.

Waschke KF, Frietsch T. Modified haemoglobins and perflurocarbons. Curr Opin Anaesthesiol. 1999;12:195-202.

Chang TMS. Future Perspectives of Blood Substitutes, em Chang TMS - Blood Substitutes, Principles, Methods, Products and Clinical Trials, Basel, S. Karger AG. 1997;1:88-110.